{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/management/prevention/","result":{"pageContext":{"chapter":{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention","depth":2,"htmlHeader":"<!-- begin field fc72f0ea-1ab2-46f2-bb69-2cdb8be8ce7b --><h2>Scenario: Prevention</h2><!-- end field fc72f0ea-1ab2-46f2-bb69-2cdb8be8ce7b -->","summary":"Covers measures that can be taken to prevent infection with human papillomavirus infection, including immunization and advice on safer sex.","htmlStringContent":"<!-- begin item 092c19df-2f5d-4b0a-afb7-23183e7a1c34 --><!-- begin field 54fab14a-bdbe-4ea9-b913-acbc0159f554 --><p>From age 16 years onwards (Female).</p><!-- end field 54fab14a-bdbe-4ea9-b913-acbc0159f554 --><!-- end item 092c19df-2f5d-4b0a-afb7-23183e7a1c34 -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"31a9dd9e-5cbb-5a09-9c88-4f55de0d1feb","slug":"prevention","fullItemName":"Prevention","depth":3,"htmlHeader":"<!-- begin field 6df0f195-2d4c-44b7-808d-241b796f397b --><h3>How can cervical cancer be prevented? </h3><!-- end field 6df0f195-2d4c-44b7-808d-241b796f397b -->","summary":null,"htmlStringContent":"<!-- begin item c5fabb0b-8264-487e-8162-27bac55859dd --><!-- begin field ee16411c-99b2-4d59-9fbb-1964285e78ce --><ul><li>Encourage women to participate in the NHS cervical screening programme (NHSCSP) — available to women 25–64 years of age in England. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-screening/\">Cervical screening</a>.</li><li>Encourage girls aged 12–13 years to receive immunization with the human papillomavirus (HPV) vaccine as part of the Childhood Immunization Programme.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-childhood/\">Immunizations - childhood</a>.</li><li>For optimum effectiveness, HPV vaccination must be given before the woman becomes sexually active.</li><li>Gardasil<sup>® </sup>quadrivalent vaccine (covering HPV types 16 and 18, and types 6 and 11 giving additional protection against genital warts) should be used.</li></ul></li><li>Inform women about practising safe sex and the use of condoms. Explain that:<ul><li>Condom use may lower the risk of HPV, but does not offer full protection, as HPV can infect areas not covered by a condom.</li><li>Condoms also protect against other sexually transmitted diseases, which are a risk factor for progression of cervical cancer (for example HIV).</li><li>Limiting the number of sexual partners reduces potential exposure to HPV infection.</li></ul></li></ul><!-- end field ee16411c-99b2-4d59-9fbb-1964285e78ce --><!-- end item c5fabb0b-8264-487e-8162-27bac55859dd -->","subChapters":[{"id":"08381942-813d-57f6-aa79-1f78239bd615","slug":"basis-for-recommendation-f12","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6b2ff67b-12c6-40fd-8743-929d2962ebb1 --><h4>Basis for recommendation</h4><!-- end field 6b2ff67b-12c6-40fd-8743-929d2962ebb1 -->","summary":null,"htmlStringContent":"<!-- begin item f122d274-f953-4ea7-be3f-d2a1b182c41d --><!-- begin field 7eee6f59-5ebc-4772-8d06-c90f0cf8ce1d --><p>These recommendations are based on the Public Health England (PHE) guideline <em>Colposcopy and programme management: guidelines for the NHS cervical screening programme </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>], the World Health Organization (WHO) position paper <em>Human papillomavirus vaccines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>] and the U.S Centers for Disease Control and Prevention (CDC) fact sheet <em>Genital HPV infection </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">CDC, 2014</a>].</p><h5>Human papillomavirus (HPV) immunization</h5><ul><li>The HPV vaccine should be administered before the onset of sexual activity and exposure to HPV infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>].<ul><li>There is no evidence of HPV vaccine efficacy in preventing vaccine type HPV-associated pre-cancer in women who had evidence of prior HPV exposure.</li></ul></li><li>The quadrivalent HPV vaccine (Gardasil<sup>®</sup>) is highly effective at preventing susceptible women from being infected with HPV types 6, 11, 16, and 18 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>].<ul><li>It is highly effective [100% (95% CI: 90.5– 100)] at preventing pre-cancerous lesions associated with HPV types 16 and 18. </li><li>It is also almost 100% effective in preventing genital warts associated with HPV types 6 and 11.</li></ul></li><li>Both the bivalent and the quadrivalent vaccines provide some cross-protection against other HPV genotypes not included in the vaccine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>].</li><li>Protection from HPV is maintained for at least 10 years after immunization [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>]. </li></ul><!-- end field 7eee6f59-5ebc-4772-8d06-c90f0cf8ce1d --><!-- end item f122d274-f953-4ea7-be3f-d2a1b182c41d -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}